The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies who supply more than 80 per cent of all branded medicines used by the NHS and who are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome disease.
Globally our industry is researching and developing more than 7,000 new medicines.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry for statutory consultation requirements including the pricing scheme for medicines in the UK.
Notes to editors
Netherlands-based Norgine is the largest employer in the pharmaceutical manufacturing sector in Wales with around 400 staff based at their state-of-the-art site in Hengoed, Wales. They employ a further 370 staff at their Harefield site in England from which their global operations are jointly run along with Norgine's headquarters in Amsterdam.
Norgine opened its UK manufacturing site in 1969 and has recently been identified as a regionally important 'anchor company' by the Welsh Government because of their contributions to the Life Science sector and significant investment in Wales. In 2010, Norgine opened a new research and development centre at Hengoed and, in 2015, opened an adjacent £4.5m temperature controlled warehouse.
Norgine are currently focused on the development, manufacturing and marketing operations of speciality medicines and medical devices in gastroenterology, hepatology, cancer and supportive care.